A Newly Identified Biomarker Panel Shows Promise in Earlier Pancreatic Cancer Detection (Part 1/2)
In short
A blood test combining two biomarkers — THBS2 and CA19-9 — correctly identified pancreatic cancer at early stages (I and II) with 87% sensitivity and 98% specificity in a research study. The test is inexpensive and could be run at standard diagnostic centers, offering real hope for people at high risk who currently have no reliable early-detection option.
- •Ask your doctor whether you qualify as high risk — this includes first-degree relatives of pancreatic cancer patients, people with a genetic predisposition, or those who developed diabetes suddenly after age 50.
- •Ask your doctor about the THBS2 + CA19-9 biomarker panel and whether clinical trials testing it in high-risk individuals are available near you.
- •Understand that this test is still in research stages — more trials are needed before it becomes a standard screening tool, so discuss realistic timelines with your care team.
- •If you are at high risk, talk to your doctor now about a monitoring plan, since catching pancreatic cancer before stage I is the goal researchers are working toward.
Ask anything about this — free, no signup
Instant answers grounded in real guidelines, not the internet.
While there have been some strides made in the treatment of pancreatic cancer, the majority of patients are diagnosed at later stages of the disease when treatment is less effective. That’s why researchers across the globe have been looking for ways in which pancreatic cancer may be found earlier. It has been a persistent scientific challenge.
However, a new study published in the journal Science Translational Medicine shows that a pair of biomarkers in the blood picked up pancreatic cancer in human cancer cells at different stages of tumor growth. This new finding is providing scientists—and patients—with new hope in the challenge of finding the disease before it has spread, and perhaps even before pancreatic cancer develops into early-stage disease.
“Although we are still early in the process, the test needs to be refined and more trials need to be done. I am excited about this both from a scientific and academic perspective, but also and most importantly, for the patients that may eventually be helped,” says study co-author Dr. Ken Zaret , director of the Penn Institute for Regenerative Medicine and the Joseph Leidy Professor of Cell and Developmental Biology.
The two-pronged biomarker panel includes plasma thrombospondin-2 (THBS2), which was combined with a known later-stage biomarker called CA19-9. Together, these biomarkers had 87 percent sensitivity, meaning that's how often they can correctly identify someone with stage I or II pancreatic cancer. They also had 98 percent specificity, meaning the combination test could accurately rule out cancer in a person who doesn't have it.
"This biomarker panel is inexpensive and it’s conventional so it could be performed at diagnostic centers pretty easily,” Zaret says. A Meticulous Process The study involved a meticulous, multi-step process that included the identification of potential biomarkers followed by work to confirm whether these potential biomarkers could accurately identify cancer. Identification of these biomarkers is no easy task.
But with expertise in genetics and stem cell biology, Zaret took late-stage pancreatic cancer cells and reprogrammed these cells into a state similar to embryonic stem cells. These cells were then able to differentiate, or change, and progress from early to late stage pancreatic cancer.
"The thought was that if we could take a late-stage cancer cell and make it into an early stem cell, there was a chance it would redevelop the cancer, undergo a progression, and basically not go into a late-stage right away," Zaret said, adding that much biomarker researcher has been focused on late-stage pancreatic cancer tissue provided post-surgery.
“You work with what you get, but I didn’t think this was a good approach to finding early-stage markers,” he said. The next step involved looking for proteins that are found in low levels in our blood. One of those proteins was THBS2, which was elevated in blood samples from 81 pancreatic cancer patients compared to a control group of 80 people without the disease.
But the results of this phase needed more fine-tuning in terms of sensitivity and specificity. So the researchers combined THBS2 with CA19-9, which has been shown to be a sensitive marker for pancreatic, gastric, and hepatobiliary malignancies, such as cancer of the liver, bile ducts, and biliary tract.
During this phase, the researchers analyzed samples from 197 cancer patients, a control group of 140 people without pancreatic cancer, and 200 people with pancreatic problems that weren't linked to cancer. It was this combination that increased the test’s accuracy. The Next Step The investigators now plan to test and validate blood samples collected from pancreatic cancer patients before they were diagnosed.
The hope is the test could eventually be used in pancreatic cancer patients and individuals with a high risk for developing the disease, such as first-degree relatives, those with a genetic predisposition, or people with a sudden onset of diabetes after age 50. What Zaret hopes is the test will eventually be refined enough to find pancreatic cancer even before it reaches stage I, which has a five-year survival rate of about 12 to 14 percent.
“I remember a surgeon telling me once that you want to be able to find pancreatic cancer even before a patient even needs to have surgery, so our goal would be to find it at stage minus one,” says Zaret, adding that additional studies and clinical trials that will test the approach in high-risk individuals are already being planned. “If doctors can find the pancreatic cancer earlier there is the hope of higher survival rates,” he says.
Highlights
from ASCO GI 2026 Survivor Stories January 28, 2026 • 3 Min Catching It Early and Moving Fast Managing Your Care January 22, 2026 • 3 Min PancChat Gets a New Home: A Podcast You Can Press “Play” On Ask the Doctor If you are in long-term treatment or have completed treatment, you may have concerns about what is next. Here are some questions to ask your doctor.
Related pancreatic questions
- →Need recommendations for pancreatic cancer stage 4 that has spread to the liver. What treatment options are available
- →What are the must haves for someone soon to be receiving chemo by port for next 3 months, then followed by surgery?...
- →What is the real-world experience with daraxonrasib for metastatic pancreatic cancer, and how do patients tolerate it
- →What are the treatment options for Pancreatic Cancer
- →Which biomarker tests (KRAS, BRCA1/2) are recommended for my Pancreatic Cancer, and how will the results guide my...
- →What fertility preservation options exist before Pancreatic Cancer treatment in young adults
- →What is a multidisciplinary tumor board and should my Pancreatic Cancer case be presented
- →What is the 5-year survival rate for pancreatic cancer
Want to learn more about your specific case?
Upload your medical records and ask Navis questions tailored to your diagnosis.